Antidepressants can treat inflammatory bowel disease through regulation of the nuclear factor-κB/nitric oxide pathway and inhibition of cytokine production: A hypothesis.

Inflammatory bowel disease (IBD) is a group of inflammatory disorders mainly affecting the colon and small intestine. The main types of IBD are Crohn's disease (CD) and ulcerative colitis (UC). UC is restricted to the large intestine whereas CD can affect any part of the gastrointestinal tract. Treating this disorder depends on the form and level of severity. Common treatment involves an anti-inflammatory drug, such as mesalazine, and an immunosuppressant, such as prednisone. Several signaling pathways, including nuclear factor (NF)-κB and nitric oxide (NO), and genetic and environmental factors are believed to play an important role in IBD. Amitriptyline is a commonly used antidepressant with known anti-inflammatory activities. Amitriptyline also acts on the NF-κB/NO pathway or cytokine production. Therefore, we hypothesize that antidepressants like amitriptyline can be pioneered and considered effective as an innovative and effective therapeutic in the treatment and attenuation of development of IBD in adjusted doses.

[1]  J. Hampe,et al.  Activation of nuclear factor κB in inflammatory bowel disease , 1998, Gut.

[2]  Jhi-Joung Wang,et al.  Amitriptyline Suppresses Neuroinflammation-dependent Interleukin-10-p38 Mitogen-activated Protein Kinase-Heme Oxygenase-1 Signaling Pathway in Chronic Morphine-infused Rats , 2009, Anesthesiology.

[3]  H. Rahimi,et al.  Association of interleukin-15 single nucleotide polymorphisms with resistance to brucellosis among Iranian patients. , 2011, Tissue antigens.

[4]  G. J. Alves,et al.  Amitriptyline and Acute Inflammation: A Study Using Intravital Microscopy and the Carrageenan-Induced Paw Edema Model , 2010, Pharmacology.

[5]  P. Navas,et al.  Acute oxidant damage promoted on cancer cells by amitriptyline in comparison with some common chemotherapeutic drugs , 2010, Anti-cancer drugs.

[6]  J. Andrews,et al.  Antidepressants and inflammatory bowel disease: a systematic review , 2006, Clinical practice and epidemiology in mental health : CP & EMH.

[7]  S. Stephens,et al.  Cytokines in stools of children with inflammatory bowel disease or infective diarrhoea. , 1993, Journal of clinical pathology.

[8]  M. Minaiyan,et al.  The role of central mechanisms in the anti-inflammatory effect of amitriptyline on carrageenan-induced paw edema in rats , 2010, Clinics.

[9]  N. D. de Wit,et al.  Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. , 2011, The Cochrane database of systematic reviews.

[10]  S. El-Shenawy,et al.  Evaluation of the anti-inflammatory and anti-nociceptive effects of different antidepressants in the rat. , 2003, Pharmacological research.

[11]  M. Hotopf,et al.  Amitriptyline for depression. , 2007, The Cochrane database of systematic reviews.

[12]  W. Sandborn,et al.  Epidemiology of inflammatory bowel disease. , 2002, Gastroenterology clinics of North America.

[13]  M. Briley,et al.  Antidepressants in the treatment of fibromyalgia , 2006, Neuropsychiatric disease and treatment.

[14]  M. Maes,et al.  The effect of repeated amitriptyline and desipramine administration on cytokine release in C57BL/6 mice , 2000, Psychoneuroendocrinology.

[15]  R. Malekzadeh,et al.  Clinical trial: the effect of amitriptyline in patients with diarrhoea‐predominant irritable bowel syndrome , 2008, Alimentary pharmacology & therapeutics.

[16]  S. Nikfar,et al.  A Comprehensive Review of Antibiotics in Clinical Trials for Inflammatory Bowel Disease , 2012 .

[17]  Sunita M. Jain,et al.  Treatment of inflammatory bowel disease (IBD) , 2011, Pharmacological reports : PR.